Pluri Inc. Deferred Income Tax Expense (Benefit)
Pluri Inc. (PLUR) reported Deferred Income Tax Expense (Benefit) of -$32.00 thousand for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-10.
Financial Statements › Cash Flow › Operating Activities
us-gaap:DeferredIncomeTaxExpenseBenefit · last filed 2026-09-10
- Pluri Inc. deferred income tax expense (benefit) for fiscal 2026 was -$32.00K.
- Pluri Inc. deferred income tax expense (benefit) for fiscal 2025 was -$5.00K.
| Period end | Deferred Income Tax Expense (Benefit) 12 month |
|---|---|
| 2026-06-30 | -$32.00K 10-K · filed 2026-09-10 |
| 2025-06-30 | -$5.00K 10-K · filed 2026-09-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B |